ECM
ABCL icon

Evergreen Capital Management’s AbCellera Biologics ABCL Stock Holding History

Evergreen Capital Management’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-11,633
Closed -$25.9K – 1134
2025
Q1 		$25.9K Sell
11,633
-16,656
-59% -$47.8K ﹤0.01% 1088
2024
Q4 		$82.9K Buy
28,289
+16,387
+138% +$45.6K ﹤0.01% 1051
2024
Q3 		$30.9K Buy
11,902
+1,217
+11% +$3.37K ﹤0.01% 1001
2024
Q2 		$31.6K Buy
+10,685
New +$40.4K ﹤0.01% 940

Other funds holding ABCL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Evergreen Capital Management's ABCL Position: Q2 2025 in Review

Evergreen Capital Management sold out of AbCellera Biologics (ABCL) in Q2 2025, closing a stake of 11,633 shares — an estimated $25.9K sold.

Evergreen Capital Management first reported a position in ABCL in Q2 2024 and held it in 4 quarters. The position peaked at $82.9K in Q4 2024. 128 funds tracked by Wall St. Rank hold ABCL as of Q2 2025.

  • Evergreen Capital Management reported no remaining AbCellera Biologics position as of Q2 2025 after selling out during the quarter.
  • Evergreen Capital Management sold 11,633 AbCellera Biologics shares in Q2 2025, an estimated $25.9K.
  • Evergreen Capital Management first reported a position in AbCellera Biologics in Q2 2024 and held it in 4 quarters.
  • Evergreen Capital Management's AbCellera Biologics position peaked at $82.9K in Q4 2024.
  • 128 funds tracked by Wall St. Rank held AbCellera Biologics as of Q2 2025.

Based on Evergreen Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.